Blue Earth Diagnostics products

Nuclear medicine is a medical speciality that uses targeted radioactive compounds, called radiopharmaceuticals, to diagnose, stage, treat and monitor diseases. Nuclear medicine can be divided into two categories: diagnostic nuclear medicine (or molecular imaging) and therapeutic nuclear medicine (or theranostics). The nuclear medicine market is predicted to reach $30 billion by 2030. Whilst molecular imaging has accounted for more than 85% of the nuclear medicine market to date, theranostics are expected to drive growth in the sector and represent more than 60% of the market by 2030. Source: MEDraysintell Nuclear Medicine Report and Directory-Edition 2019.

Diagnostic nuclear medicine is a type of molecular imaging that uses very small amounts of radioisotopes attached to a targeting molecule (radiopharmaceutical¹) to diagnose complex diseases such as cancer. Radiopharmaceuticals are able to show the physiological function of the body rather than just the anatomy. Changes in the biochemical activity of cells often characterises disease. For example, cancer cells multiply at a much faster rate and are more active than normal cells, therefore and often have a high demand for precursors such as amino acids to build proteins. Radiopharmaceuticals can provide images of what is occurring inside the body at molecular and cellular levels. Depending upon where the patient is in the course of their disease, such a unique insight into the human body may enable physicians to personalise patient care.

Therapeutic nuclear medicine, also known as theranostics, combines tumour targeting with a therapeutic dose of radiation. Tumour targeting allows radiopharmaceuticals to selectively target cells associated with disease due to the affinity between the drug and certain receptors expressed by the relevant cells. The targeting molecule delivers a therapeutic dose of radiation to kill tumour cells. Blue Earth Diagnostics acquired exclusive, worldwide rights to radiohybrid Prostate Specific Membrane Antigen (rhPSMA) targeted technology in order to expand its oncology imaging and theranostics portfolio. The Company is investigating the use of rhPSMA (18F) as a diagnostic imaging agent for prostate cancer in addition to exploring promising therapeutic leads for treatment of the disease.